CRIS Foundation develops therapies with "intelligent antibodies" against ovarian cancer tumor cells

Targeted conjugated antibodies (ADCs) are added to PARP inhibitor drugs (iPARPs) that have revolutionized the treatment of advanced ovarian cancer, especially in patients with BRCA mutations or specific genomic alternations, both relapsed and in first-line treatment. The impact on survival is clear in patients with BRCA germline mutations, along with an improvement in quality of life. These advances represent a paradigm shift in disease manageme…

The CRIS Anti-Cancer Foundation leads two projects for the treatment of ovarian cancer based on "intelligent antibodies", that is, antibodies conjugated to drugs (ADC) that attack only tumor cells, preserve the patient's healthy tissue and block tumor growth.